What is Curza?
Curza is a small-molecule therapeutics company dedicated to developing novel classes of antibiotics to combat the escalating threat of antibiotic resistance. The company's lead program, CZ-02, is engineered to target drug-resistant Gram-negative bacteria and ESKAPE pathogens. Through proprietary drug design, Curza has demonstrated potent activity against various infectious diseases, including those associated with biofilms, positioning itself as a key innovator in the critical field of antibiotic development.
How much funding has Curza raised?
Curza has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Curza
PPP
Public-Private Partnership
What's next for Curza?
With a substantial late-stage funding context, Curza is poised for significant expansion and the advancement of its therapeutic pipeline. The recent strategic investment will likely fuel further clinical trials, scale manufacturing capabilities, and potentially broaden its market reach. This capital infusion is critical for addressing urgent global health challenges and solidifying its position in the fight against antimicrobial resistance.
See full Curza company page
